A woman presented with at least four manifestations of varicella-zoster virus (VZV) infection, including central nervous system vasculitis, during her first 2 years of HIV infection. We evaluated her CD4 T cell responses to VZV given the infrequency with which multiple recurrences of VZV occurred, especially following immune reconstitution on antiretroviral therapy.
Get full access to this article
View all access options for this article.
References
1.
BarnabasRV, BaetenJM, LingappaJR, et al.Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: results of a randomized clinical trial. J Infect Dis, 2016; 213:551–555.
2.
BoeckhM, KimHW, FlowersME, et al.Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood, 2006; 107:1800–1805.
3.
CohenJI. Herpes zoster. N Engl J Med, 2013; 369:255–263.
4.
CostiniukCT, FergussonDA, DoucetteS, et al.Discontinuation of pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/μL and virologic suppression: a systematic review. PLoS One, 2011; 6:e28570.
5.
D'EgidioGE, KravcikS, CooperCL, et al.Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count <200 cells/μL when viral replication is suppressed. AIDS, 2007; 21:1711–1715.
6.
De La BlanchardiereA, RozenbergF, CaumesE, et al.Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand J Infect Dis, 2000; 32:263–269.
7.
GilbertPB, GabrielEE, MiaoX, et al.Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis, 2014; 210:1573–1581.
8.
GrabarS, TattevinP, Selinger-LenemanH, et al.Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis, 2015; 60:1269–1277.
9.
HaanpaaM, DastidarP, WeinbergA, et al.CSF and MRI findings in patients with acute herpes zoster. Neurology, 1998; 51:1405–1411.
10.
JingL, LaingKJ, DongL, et al.Extensive CD4 and CD8 T cell cross-reactivity between alphaherpesviruses. J Immunol, 2016; 196:2205–2218.
11.
LaingKJ, DongL, SidneyJ, et al.Immunology in the clinic review series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol, 2012; 167:47–58.
12.
LaingKJ, MagaretAS, MuellerDE, et al.Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol, 2010; 30:703–722.
13.
LaingKJ, RussellRM, DongL, et al.Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J Infect Dis, 2015; 212:1022–1031.
14.
LalH, CunninghamAL, GodeauxO, et al.Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med, 2015; 372:2087–2096.
15.
LiC-R, GreenbergP, GilbertM, et al.Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood, 1994; 83:1971–1979.
16.
LiuC, WangC, GlesbyMJ, et al.Effects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study. AIDS Res Ther, 2013; 10:34.
17.
LyckeJ, MalmeströmC, StåhleL. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother, 2003; 47:2438–2441.
18.
OuwendijkWJ, LaingKJ, VerjansGM, et al.T-cell immunity to human alphaherpesviruses. Curr Opin Virol, 2013; 3:452–460.
19.
RubinLG, LevinMJ, LjungmanP, et al.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 2014; 58:e44–e100.
20.
TeoSY, RahaD, WarrenD, et al.Central nervous system-immune reconstitution inflammatory syndrome presenting as varicella zoster virus-mediated vasculitis causing stroke. Int J STD AIDS, 2014; 25:683–685.
21.
YangcoBG, BuchaczK, BakerR, et al.Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?. AIDS Patient Care STDS, 2014; 28:280–283.
